|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Revisiting the frontiers of phar- macogenomics of colon cancer 显示文摘 | Falandry C Bonnefoy M Freyer G | 2011 | Pharmacogenomics2011，12，9： | 1 |
| 2 | Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients:a double-blind phaseⅢGINECO study显示文摘 | Falandry C Debled M Bachelot T | 2009 | Breast Cancer Res Treat2009，116，3： | 1 |
| 3 | Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients:a double-blind phase Ⅲ GINECO study显示文摘 | Falandry C Debled M Bachelot T | 2009 | Breast Cancer Res Treat2009，116，3： | 1 |
| 4 | Biology of cancer and aging: a complex association with cellular senescence 显示文摘 | Falandry C Bonnefoy M Freyer G | 2014 | J Clin Oncol2014，32，24： | 1 |
| 5 | Are aging biomarkers clini- cally relevant in oncogeriatrics 显示文摘 | Falandry C Gilson E Rudolph K L | 2013 | Crit Rev Oncol Hematol2013，85，： | 1 |
| 6 | Celecoxib and exemestane versus placebo and exemestane in postmenopausalmetastatic breast cancer patients: a double-blind phase Ⅲ gineco study显示文摘 | Falandry C Debled M Bachelot T | 2009 | Breast Cancer Res Treat2009，116，3： | 1 |
| 7 | CLLD8/KMT1F is a lysine methyhransferase that is important for chromosome segaega- tion显示文摘 | Falandry C Fourel G Galy V | 2010 | J Biol Chem2010，285，20： | 1 |
| 8 | Utilization of a pedicled labial flap,single or double face,for the management of postobstetric urethral damage显示文摘 | Falandry L Xie D Liang Z | 1999 | J Gynecol Obstet Biol Re- prod (Paris)1999，28，： | 1 |
| 9 | Ureterovaginal fistulas:diagnosis and surgical tactic 显示文摘 | Falandry L | 1992 | J Urol1992，98，4： | 1 |
| 10 | Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer 显示文摘 | Falandry C Canney PA Freyer G | 2009 | Ann Oncol2009，20，4： | 1 |
| 11 | Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study 显示文摘 | Falandry C Debled M Bachelot T | 2009 | Breast Cancer Res Treat2009，116，3： | 1 |
| 12 | Trends in G-CSF use in 990 patients after EORTC and ASCO guidelines显示文摘 | FALANDRY C CAMPONE M CARTRON G | 2010 | EurJ Cancer2010，46，13： | 1 |
| 13 | Cytoreductive Surgery and Intraperitoneal Chemohyperthermia for Chemoresistant and Recurrent Advanced Epithelial Ovarian Cancer: Prospective Study of 81 Patients显示文摘 | Eddy Cotte Olivier Glehen Faheez Mohamed Franck Lamy Claire Falandry Fran?ois Golfier Francois Noel Gilly | 2007 | World Journal of Surgery2007，，9： | 1 |
| 14 | Cytoreductive Surgery and Intraperitoneal Chemohyperthermia for Chemoresistant and Recurrent Advanced Epithelial Ovarian Cancer: Prospective Study of 81 Patients显示文摘 | Eddy Cotte Olivier Glehen Faheez Mohamed Franck Lamy Claire Falandry Fran?ois Golfier Francois Noel Gilly | 2007 | World Journal of Surgery2007，，9： | 1 |
| 15 | Role of com-bination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer显示文摘 | Falandry C Canney PA Freyer G | | 0，，04： | 1 |
| 16 | Biology of cancer and aging: a complex association with cellular senescence 显示文摘 | Falandry C Bonnefoy M Freyer G | 2014 | J Clin Oncol2014，32，24： | 1 |
| 17 | Utilization of a pedicled labial flap,single or double face,for the management of postobstetric uretharl damage 显示文摘 | Falandry L Xie D Liang Z | 1999 | J Gynecol Obstet Biol Reprod(Paris)1999，28，： | 1 |
| 18 | Role of combination therapy with aromatase and cyclooxygenase -2 inbibitors in patients with metastatic breast cancer 显示文摘 | Falandry C Canney PA Freyer G | 2009 | Ann Oncol2009，20，4： | 1 |
| 19 | C elecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast canser patients:a double-blind phase GINECO study显示文摘 | Falandry C Deb led M Bachelot T | 2009 | Breast Cancer Res Treat2009，116，3： | 1 |
| 20 | Screening for hypertension-mediated organ damage and aetiology:still of value after 65 years of age?显示文摘BACKGROUND Secondary forms and hypertension-mediated organ damage(HMOD) may differ between younger and older hypertensive patients.The aim of the present study was to explore the specificity of HMOD and secondary forms in patients≥ 65 years in comparison to younger ones in a contemporary cohort.METHODS We analysed 938 patients recruited between 2004 and 2014(Cardiology department,Croix-Rousse Hospital,Lyon)who had at baseline HMOD and secondary forms screening among them 190 were≥ 65 years.RESULTS The mean(2.1±0.8 vs.1.2±0.9,P <0.001) and frequency of HMOD(96.3% vs.72.9%,P <0.001) was higher in patients≥ 65 years than younger ones.Carotid femoral pulse wave velocity> 10 m/s was the most frequent HMOD in patients≥ 65 years(90.1%),while echocardiographic left ventricular hypertrophy was the most common in the younger patients(45.0%).Among ECG left ventricular indexes,only R wave in aVL lead was significantly more frequently observed in patients≥ 65 years(32.6%) than in younger ones(19.0%,P <0.001).The frequency of secondary hypertension was not significantly different between younger and older patients(respectively;30.5% vs.27.8%,P=0.487).The most frequent aetiology was primary aldosteronism regardless of age,followed by renovascular hypertension(6.3% vs.3.3%,P=0.038).Among older patients,3.2% were treated with adrenalectomy and 6.3% with percutaneous transluminal renal angioplasty.CONCLUSION Extensive screening of HMOD in older patients may be questionable as nearly all patients had one;aetiology must however be explored as a third of older patients had a secondary form. | Delphine Thiolliere Brahim Harbaoui Claire Falandry Marc Bonnefoy Jean-Christophe Lega Pierre Lantelme Pierre-Yves Courand | 2022 | Journal of Geriatric Cardiology2022，19，11： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员